Summary
This 8-K filing from Alnylam Pharmaceuticals, Inc. (ALNY) announces a CFO transition and related executive arrangements. Manmeet S. Soni will be resigning as Senior Vice President, Chief Financial Officer (CFO) effective August 12, 2019, and will provide transition assistance and consulting services for up to a year. In connection with his departure, Mr. Soni will receive a severance package including salary continuation and COBRA premium coverage. Alnylam is appointing Jeffrey Poulton as its new CFO, effective August 13, 2019. Mr. Poulton brings extensive financial leadership experience, including his most recent role as CFO of Indigo Ag, and prior significant roles at Shire plc. His compensation package includes a base salary, annual bonus potential, and a stock option grant. This transition is intended to ensure continuity in financial leadership and reporting for the company.
Key Highlights
- 1Manmeet S. Soni resigns as CFO, effective August 12, 2019, after a transition period.
- 2Mr. Soni will receive 12 months of salary continuation and COBRA premium coverage as severance.
- 3Mr. Soni will provide consulting services for up to one year post-separation, with continued vesting of equity awards.
- 4Jeffrey Poulton appointed as new CFO, effective August 13, 2019.
- 5Mr. Poulton has significant prior experience as CFO of Indigo Ag and Shire plc.
- 6Mr. Poulton's compensation includes a base salary of $530,000, annual bonus potential, and a stock option grant for 125,000 shares.
- 7The company issued a press release on July 11, 2019, announcing the CFO change, which is furnished with this filing.